[HTML][HTML] Exosomal microRNA predicts and protects against severe bronchopulmonary dysplasia in extremely premature infants

CV Lal, N Olave, C Travers, G Rezonzew, K Dolma… - JCI insight, 2018 - ncbi.nlm.nih.gov
Premature infants are at high risk for developing bronchopulmonary dysplasia (BPD),
characterized by chronic inflammation and inhibition of lung development, which we have …

Emerging roles of extracellular vesicles in neurodegenerative disorders

Y You, T Ikezu - Neurobiology of Disease, 2019 - Elsevier
Extracellular vesicles (EVs) are heterogeneous cell-derived membranous vesicles which
carry a large diversity of molecules such as proteins and RNA species. They are now …

The complex relationships between microglia, alpha-synuclein, and LRRK2 in Parkinson's disease

J Schapansky, JD Nardozzi, MJ LaVoie - Neuroscience, 2015 - Elsevier
The proteins alpha-synuclein (αSyn) and leucine rich repeat kinase 2 (LRRK2) are both key
players in the pathogenesis of the neurodegenerative disorder Parkinson's disease (PD) …

[HTML][HTML] Extracellular vesicles in the diagnosis and treatment of central nervous system diseases

AA Shaimardanova, VV Solovyeva… - Neural regeneration …, 2020 - journals.lww.com
Extracellular vesicles, including exosomes and microvesicles, play a fundamental role in the
activity of the nervous system, participating in signal transmission between neurons and …

[HTML][HTML] Selective LRRK2 kinase inhibition reduces phosphorylation of endogenous Rab10 and Rab12 in human peripheral mononuclear blood cells

K Thirstrup, JC Dächsel, FS Oppermann… - Scientific reports, 2017 - nature.com
Genetic variation in the leucine-rich repeat kinase 2 (LRRK2) gene is associated with risk of
familial and sporadic Parkinson's disease (PD). To support clinical development of LRRK2 …

Parkinson-related LRRK2 mutation R1441C/G/H impairs PKA phosphorylation of LRRK2 and disrupts its interaction with 14-3-3

K Muda, D Bertinetti, F Gesellchen… - Proceedings of the …, 2014 - National Acad Sciences
Leucine-rich repeat kinase 2 (LRRK2) is a multidomain protein implicated in Parkinson
disease (PD); however, the molecular mechanism and mode of action of this protein remain …

The dopamine transporter antagonist vanoxerine inhibits G9a and suppresses cancer stem cell functions in colon tumors

CJ Bergin, A Zouggar, A Mendes da Silva, T Fenouil… - Nature Cancer, 2024 - nature.com
Cancer stem cells (CSCs), functionally characterized by self-renewal and tumor-initiating
activity, contribute to decreased tumor immunogenicity, while fostering tumor growth and …

The dynamic switch mechanism that leads to activation of LRRK2 is embedded in the DFGψ motif in the kinase domain

SH Schmidt, MJ Knape, D Boassa… - Proceedings of the …, 2019 - National Acad Sciences
Leucine-rich repeat kinase 2 (LRRK2) is a large multidomain protein, and LRRK2 mutants
are recognized risk factors for Parkinson's disease (PD). Although the precise mechanisms …

Exosomes and their application in biomedical field: difficulties and advantages

J Rezaie, S Ajezi, ÇB Avci, M Karimipour… - Molecular …, 2018 - Springer
The science of gene therapy has experienced a controversial history. At first, the initial
concept that various disorders become curable by gene transferring was very exciting and …

[HTML][HTML] LRRK2 phosphorylation, more than an epiphenomenon

A Marchand, M Drouyer, A Sarchione… - Frontiers in …, 2020 - frontiersin.org
Mutations in the Leucine Rich Repeat Kinase 2 (LRRK2) gene are linked to autosomal
dominant Parkinson's disease (PD), and genetic variations at the LRRK2 locus are …